前列腺特异性膜抗原正电子发射断层扫描在前列腺癌诊断与根治前原发分期中作用的系统综述与Meta分析
该系统综述与Meta分析纳入12项研究共1533例用于前列腺内诊断、99项研究共18649例用于分期,评估PSMA PET对临床显著前列腺癌(csPCa)的诊断准确性及原发分期中转移检出率。PSMA PET诊断csPCa的敏感度82%、特异度67%、阳性预测值77%、阴性预测值73%,与MRI联合时AUC升至88%;分期中前列腺外阳性率23%,高危亚组31%、中危亚组12%;以盆腔淋巴结清扫为参考标准时敏感度54%、特异度94%。作者认为PSMA PET阴性不足以省略活检,且不能单独决定是否行淋巴结清扫。
要点
- PSMA PET诊断csPCa的敏感度82%、特异度67%、阳性预测值77%、阴性预测值73%。
- PSMA PET联合MRI诊断csPCa的AUC为88%,高于单用PSMA PET的84%。
- 原发分期中PSMA PET前列腺外阳性率23%,高危亚组31%、中危亚组12%。
核心结论
- PSMA PET对鉴别csPCa具有良好准确性,尤其在与MRI联合时,但阴性预测值不足以省略活检。
- 分期方面,PSMA PET不能单独用于决定是否需要淋巴结清扫,应与预测工具中的其他临床信息结合。
- 作者认为,进一步研究应开发并验证纳入PSMA PET的模型,以可靠地指导活检或淋巴结清扫。
研究设计与样本
- 系统综述与Meta分析,检索PubMed/MEDLINE、Cochrane library的CENTRAL、EMBASE和Scopus数据库,从建库至2024年4月。
- 主要结局一:评估PSMA PET在患者水平检测前列腺内csPCa的敏感度、特异度、阳性预测值和阴性预测值。
- 主要结局二:评估根治性治疗前原发分期中转移性疾病的阳性率。
- 次要结局:在可获得盆腔淋巴结清扫作为参考标准的研究中,以患者水平分析PSMA PET检测淋巴结侵犯的诊断准确性。
- 采用随机效应模型合并阳性率和检出率,并预设亚组分析评估不同研究队列的诊断准确性。
主要发现
- 前列腺内诊断的定量合成纳入12项研究共1533例参与者,分期定量合成纳入99项研究共18649例参与者。
- PSMA PET诊断csPCa的敏感度82%(95%CI 73-90%)、特异度67%(95%CI 46-85%)、阳性预测值77%(95%CI 63-88%)、阴性预测值73%(95%CI 56-87%)。
- 双变量分析中,PSMA PET诊断准确性的汇总受试者工作特征曲线下面积为84%,与MRI联合时升至88%。
- 分期水平上,PSMA PET前列腺外阳性率为23%,高危亚组为31%、中危亚组为12%。
- 以盆腔淋巴结清扫为参考标准(51项研究共7713例患者),PSMA PET的敏感度54%、特异度94%、阳性预测值77%、阴性预测值86%。
关键数值与推荐
- PSMA PET诊断csPCa的敏感度82%(95%CI 73-90%)、特异度67%(95%CI 46-85%)、阳性预测值77%(95%CI 63-88%)、阴性预测值73%(95%CI 56-87%)。
- PSMA PET诊断csPCa的汇总受试者工作特征曲线下面积为84%,与MRI联合时为88%。
- 原发分期中PSMA PET前列腺外阳性率23%,高危亚组31%、中危亚组12%。
- 以盆腔淋巴结清扫为参考标准,PSMA PET检测淋巴结侵犯的敏感度54%、特异度94%、阳性预测值77%、阴性预测值86%。
临床怎么用
- 作者认为PSMA PET对鉴别csPCa具有良好准确性,尤其在与MRI联合时,但阴性预测值不足以省略活检。
- 作者认为PSMA PET不能单独用于决定是否需要淋巴结清扫,应与预测工具中的其他临床信息结合。
- 作者建议进一步研究应开发并验证纳入PSMA PET的模型,以可靠地指导活检或淋巴结清扫。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) in the diagnosis and primary staging of patients with prostate cancer (PCa) has an established role, but recent summative evidence on its actual diagnostic and staging value is still missing. We aimed to collect and analyze published studies reporting the accuracy of PSMA PET for the diagnosis of clinically significant prostate cancer (csPCa) and detection of distant metastases at primary staging before definitive treatment. METHODS: We performed a systematic review of the literature, by searching the PubMed/MEDLINE, Cochrane library's CENTRAL, EMBASE, and Scopus databases, from inception to April 2024. Two coprimary outcomes were assessed: first, to evaluate the sensitivity, specificity, positive (PPV) and negative (NPV) predictive values of PSMA PET in detecting intraprostatic csPCa on a per-patient level, and second, to assess the positivity rates of metastatic disease in the primary staging, prior to definitive therapy. As a secondary outcome, the diagnostic accuracy of PET PSMA for the detection of lymph nodal invasion (LNI) was tested in a per-patient-level analysis of studies where pelvic lymph node dissection (PLND) was available as the reference standard. Positivity and detection rates were pooled using random-effect models. Preplanned subgroup analyses tested the diagnostic accuracy of PET PSMA across different study cohorts. Variation in PPV and NPV over csPCa and LNI prevalence was evaluated. KEY FINDINGS AND LIMITATIONS: In total, 12 and 99 studies, with a total of 1533 and 18 649 participants, respectively, were included in the quantitative synthesis for intraprostatic diagnosis and staging. For intraprostatic disease, the sensitivity, specificity, PPV, and NPV of PSMA PET for csPCa were 82% (95% confidence interval [CI] 73-90%), 67% (95% CI 46-85%), 77% (95% CI 63-88%), and 73% (95% CI 56-87%), respectively. At a bivariate analysis, the diagnostic accuracy of PSMA PET estimated through a summary receiver operating characteristic curve-derived area under the curve was 84%, increasing up to 88% when combined with magnetic resonance imaging (MRI). On staging level, PSMA PET results were positive outside the prostate in 23% of the patients, with substantial variation in positivity rates between high-risk (31%) and intermediate-risk (12%) subcohorts. When using PLND as the reference standard (51 studies, 7713 patients), the sensitivity, specificity, PPV, and NPV of PSMA PET were, respectively, 54%, 94%, 77%, and 86%. With higher csPCa and LNI prevalence, a similar increase in PPV and a decrease in NPV were observed. CONCLUSIONS AND CLINICAL IMPLICATIONS: The current updated systematic review and meta-analysis provides updated evidence on the diagnostic and staging accuracy of PSMA PET in PCa. We reported good accuracy of PSMA PET to discriminate csPCa, particularly when added to MRI, but NPV alone is insufficient to omit a biopsy. Regarding staging, PSMA PET cannot be used alone to determine the need for lymph node dissection (LND) and should be combined with additional clinical information within predictive tools. As such, further research should develop and validate models that incorporate PSMA PET to reliably inform biopsy or LND.
引用
- Mazzone E, Cannoletta D, Quarta L, et al. A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment. Eur Urol. 2025. PMID: 40155242. doi:10.1016/j.eururo.2025.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。